Eli Lilly and Company (LLY)
| Market Cap | 553.37B |
| Revenue (ttm) | 32.07B |
| Net Income (ttm) | 4.99B |
| Shares Out | 949.31M |
| EPS (ttm) | 5.52 |
| PE Ratio | 105.60 |
| Forward PE | 52.36 |
| Dividend | $5.20 (0.89%) |
| Ex-Dividend Date | Feb 14, 2024 |
| Volume | 1,989,702 |
| Open | 582.85 |
| Previous Close | 580.85 |
| Day's Range | 579.47 - 586.17 |
| 52-Week Range | 309.20 - 629.97 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 560.52 (-3.84%) |
| Earnings Date | Feb 6, 2024 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal... [Read more]
Financial Performance
In 2022, LLY's revenue was $28.54 billion, an increase of 0.79% compared to the previous year's $28.32 billion. Earnings were $6.24 billion, an increase of 11.88%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for LLY stock is "Buy." The 12-month stock price forecast is $560.52, which is a decrease of -3.84% from the latest price.
News
Obesity drug enthusiasm can continue in 2024: Mizuho's Jared Holz
Mizuho's Jared Holz joins 'Fast Money' to talk enthusiasm surrounding obesity drugs and if that can endure into 2024.
Lilly Completes Acquisition of POINT Biopharma
INDIANAPOLIS , Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmac...
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceutic...
Healthcare Stocks Had a Terrible 2023. Things Are Looking Up.
Things could hardly have gone worse for healthcare investors this year.
Tim Seymour shares which stocks were 'naughty or nice' in 2023
Tim Seymour, founder and CIO of Seymour Asset Management, joins 'Power Lunch' to discuss which stocks he believes are naughty or nice.
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
Wall Street turned its focus to a handful of newer treatments in different disease areas in 2023, including weight loss medications and a new Alzheimer's drug.
Ozempic overshoot will plump up bargain-hunters
Weight-loss drug excitement went overboard in 2023. Novo Nordisk's Wegovy – which is known as Ozempic when used to treat diabetes – and Eli Lilly's Zepbound are the first effective treatments for obes...
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
JERSEY CITY, N.J.--(BUSINESS WIRE) Organon becomes the sole distributor and promoter of Emgality® (galcanezumab) and RAYVOW™ (lasmiditan) in Europe.
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023
INDIANAPOLIS , Dec. 18, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares (...
The weight loss drug boom isn't over yet — here's what to expect in the year ahead
2024 will be another big year for weight loss drugs, which soared in popularity despite hefty price tags, mixed insurance coverage and unpleasant side effects.
Wells Fargo's top pharma picks for 2024
Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.
Final Trades: OILK, Eli Lilly, American Express and Humana
Here are today's final trades from the Investment Committee.
Billionaire investor Ken Langone: Lilly will be the first trillion dollar drug company in history
Ken Langone, Invemed Associates chairman and Home Depot co-founder, joins 'Squawk Box' to discuss the state of the pharmaceutical industry, including Pfizer's weaker than expected 2024 forecast, the g...
Strategist: Buy Baxter stock, skip Eli Lilly stock
Novo Nordisk (NVO) was named Yahoo Finance's Company of the Year thanks to the success of its diabetes and weight loss drugs, Ozempic and Wegovy. But there are other ways you can play the GLP-1 hype.
Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting
INDIANAPOLIS , Dec. 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent (reve...
Eli Lilly Stock Slips After Reported Weight Gain In Users Who Quit Its Drug
Eli Lilly (LLY) shares fell 2.3% Monday after a study conducted by the drug maker found patients who use its weight-loss treatments may gain weight once they stop taking the drugs.
Patients Who Stopped Using Zepbound Experienced ‘Substantial' Weight Regain, Eli Lily's Study Suggests
Patients using Eli Lilly's weight-loss drug Zepbound experienced a “substantial regain” of lost weight after withdrawing from treatment, according to a study published Monday, the latest study indicat...
Patients regain weight after stopping Eli Lilly's Zepbound, study says
The data suggests that people have to stay on the weekly injection Zepbound if they want to maintain weight loss.
Eli Lilly Stock Falls on Data That Show Patients Who Stopped Zepbound Regained Weight
A JAMA study shows that patients who stopped taking Zepbound after 36 weeks on the drug experienced a 14% weight regain over a year.
Midday Movers: Cigna Soars After Calling Off Humana Deal, Eli Lilly Falls Following Study
U.S. equities were little changed at midday ahead of key inflation data due later in the week and the final Federal Reserve policy meeting of 2023. The Dow and S&P 500 were up slightly, while the Nasd...
Here's what will happen if you stopped taking Eli Lilly's weight-loss drug
Eli Lilly & Co (NYSE: LLY) is down nearly 4.0% today after a study indicated that weight-loss from Zepbound tends to reverse once the treatment is stopped. Patients regain weight if they stop taking Z...
Patients on Eli Lilly's drug regain weight after stopping treatment - JAMA study
Patients on Eli Lilly's weight-loss drug trial substantially regained weight after stopping treatment, according to a study published in journal JAMA on Monday.
Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks
People who were randomized to placebo following the lead-in period experienced mean weight regain of 14.8% at 88 weeks, indicating Zepbound led to sustained weight loss compared to placebo Full result...
Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend
INDIANAPOLIS, Dec. 8, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quar...